Rusfertide

Brand names: Mimrylo · Active ingredient: Rusfertide Acetate

In short: MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).

Forms & strengthsFor injection: a sterile, white to off-white lyophilized powder for reconstitution in single-dose vials containing 9.5 mg, 19 mg, 28 mg, 41 mg, and 54 mg rusfertide (provided as rusfertide acetate) per vial, co-packaged with a clear diluent solution.
LabelTakeda Pharmaceuticals America, Inc.
Label updatedNov 11, 2026

What is Rusfertide used for?

MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).

Rusfertide dosage

MIMRYLO is for subcutaneous use only.

The recommended weekly dosage range of MIMRYLO is 9.5 mg to 108 mg.

The recommended starting dose of MIMRYLO is 19 mg once a week.

Doses above 54 mg will require two injections.

Doses greater than 82 mg should be administered on separate days.

Administer MIMRYLO subcutaneously on a weekly dosing schedule. See Table 1.

MIMRYLO Weekly DoseDoses higher than 54 mg are administered as 2 injections. If the weekly dosage is greater than 82 mg, administer your first injection on day 1 and the second injection on day 4 or 5. | Dosing Instructions | Frequency During Each Week

9.5 mg | Single injection | Once weekly

19 mg

28 mg

41 mg

54 mg

69 mg | 28 mg AND 41 mg | Once weekly on the Same Day

82 mg | 41 mg AND 41 mg | Once weekly on the Same Day

95 mg | Day 1: 54 mg Day 4 or 5: 41 mg | Day 1 and Day 4 or 5

108 mg | Day 1: 54 mg Day 4 or 5: 54 mg

Adjust the dose of MIMRYLO based on efficacy or safety .

Monitor complete blood count (CBC) every 2 to 4 weeks or as clinically indicated during dose modifications.

Dose increase:

After a minimum of 2 weeks at the current weekly dose, dose increase may be considered according to Table 2 and based on medical judgement to reduce or to maintain hematocrit at the recommended level below 45%. Allow a minimum of 2 weeks between dose increases.

Current Weekly Dose | Increase Weekly Dose to

9.5 mg | 19 mg

19 mg | 28 mg

28 mg | 41 mg

41 mg | 54 mg

54 mg | 69 mg

69 mg | 82 mg

82 mg | 95 mg

95 mg | 108 mg

Dose decrease:

For Grade ≥2 anemia or for drug-related Grade ≥3 toxicities, reduce the dose of MIMRYLO according to Table 3.

Current Weekly Dose | Decrease Weekly Dose to

9.5 mg | Discontinue treatment

19 mg | 9.5 mg

28 mg | 19 mg

41 mg | 28 mg

54 mg | 41 mg

69 mg | 54 mg

82 mg | 69 mg

95 mg | 82 mg

108 mg | 95 mg

For patients injecting once a week

If the injection is missed by 1 to 4 days, take the missed injection immediately and then resume regular dosing schedule.

If the injection is missed by more than 4 days, take the missed injection immediately. Take the next injection 3 days later and then resume the regular dosing schedule.

For patients injecting two times a week

If the injection is missed by 1 to 2 days, take the missed injection immediately and take the next injection 3 days later. Then resume the regular dosing schedule.

If the injection is missed by more than 2 days, skip the missed injection and continue the regular dosing schedule.

Prior to treatment initiation, healthcare providers should show patient and/or caregivers how to prepare and inject MIMRYLO subcutaneously into the abdomen, thigh, or upper arm. Advise patients and/or caregivers to contact healthcare providers with questions. …

How to take Rusfertide — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Subcutaneous Dosing Technique

Provide guidance to patients and caregivers on proper subcutaneous administration technique, and how to use MIMRYLO .

Missed Dose

Instruct patients to call healthcare provider if they are unsure when to inject a missed dose .

New or Worsening Thrombocytosis

Advise patients that MIMRYLO may increase platelet counts. Instruct patients to contact their healthcare provider if they experience signs or symptoms of bleeding or blood clots, such as unusual bruising or bleeding, chest pain, shortness of breath, leg pain or swelling, or sudden severe headache .

Injection Site Reactions

Advise patients that injection site reactions may occur with MIMRYLO. Instruct patients to contact their healthcare provider if they experience severe or persistent injection site reactions. Inform patients that ice, topical corticosteroid creams, antihistamines, or analgesics may be used to manage injection site pain and swelling .

Embryo-Fetal Toxicity

MIMRYLO may cause fetal harm. Advise females to inform their healthcare provider of a known or suspected pregnancy . …

Warnings & precautions

Do not take this medicine if: None.

MIMRYLO may increase platelet counts in patients with PV. Within 4 weeks of treatment initiation, platelet counts increased by an average of 31% from baseline. Thirty-six percent of patients had platelet counts that exceeded 600 x 109/L, and 6% had platelet counts that exceeded 1,000 x 109/L. Platelet counts generally plateaued on treatment by Week 8. MIMRYLO was discontinued due to increased platelet counts in 1% of patients.

After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Injection site reactions occurred in 135 (47%) patients treated with MIMRYLO in VERIFY. The most common (>5%) injection site reactions reported were erythema (27%), pruritus (17%), pain (15%), and swelling (8%). Two patients experienced Grade 3 injection site reactions, and all other patients experienced Grade 1 or Grade 2 injection site reactions; most did not require medication for treatment. Two patients (0.7%) experienced injection site reactions that led to treatment discontinuation. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling .

Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Administration of MIMRYLO to pregnant rats and rabbits during organogenesis resulted in structural anomalies and embryo-fetal lethality, respectively, at exposures lower than the maximum recommended human dose. Pregnancy testing is recommended for females of reproductive potential prior to treatment with MIMRYLO. …

Rusfertide side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

New or Worsening Thrombocytosis

Injection-Site Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Polycythemia Vera

VERIFY

The safety of MIMRYLO was evaluated in VERIFY , a Phase 3, randomized double-blind, placebo-controlled study in patients with PV. During the randomized controlled period (Week 0 to Week 32), 145 patients received MIMRYLO and 146 patients received placebo. Following the randomized controlled period, patients in the placebo arm crossed over to MIMRYLO, resulting in a total of 285 patients exposed to MIMRYLO during the study. The median duration of exposure to MIMRYLO was 61 weeks (range; 2 weeks to 133 weeks) with 65% of patients exposed to ≥52 weeks.

During the randomized controlled period (Week 0 to Week 32), the most common (>15%) adverse reactions in the MIMRYLO arm were injection site reactions (56%) and anemia (16%).

One (0.4%) patient experienced a serious adverse reaction of anemia. Dosage reductions of MIMRYLO due to an adverse reaction occurred in 30 (11%) patients. Adverse reactions which required dosage reduction included anemia in 28 (10%) patients, dyspnea in 2 (0.7%) patients and thrombocytosis in 1 (0.4%) patient. …

About this medicine

MIMRYLO (rusfertide) for injection, for subcutaneous use, a hepcidin mimetic, is a synthetic cyclic peptide (disulfide) isolated as an acetate salt. The chemical name for rusfertide is S6

,S16

-cyclo[N-isovaleryl-Asp-Thr-His-Phe-Pro-Cys-Ile-Nε-(N-palmitoyl-γ-Glu)-Lys-Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys-Lys-NH2] acetate.

Rusfertide acetate has the following chemical structure:

Rusfertide acetate is an amorphous white to off-white powder, light sensitive and hygroscopic with low solubility in ethanol or acetonitrile. The aqueous solubility in pH range of 2.5 to 7.4 is ≥112 mg/mL.

The average molecular weight for the free base is 2442.0 u. The molecular formula for the free base is C114H181N27O28S2.

MIMRYLO for injection is supplied as a sterile, preservative-free, white to off-white lyophilized powder in a single-dose glass vial. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 101aff01-31ed-4841-a8b6-0a5a8503189b. Read the full official label on DailyMed.